News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The expansion includes a larger technical and service team and increased local procurement
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
This recognition demonstrate excellence in intellectual property (IP) value creation.
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Subscribe To Our Newsletter & Stay Updated
